Company news
Correvio Pharma Corp news in 2018
Correvio Pharma Corp's news releases, calls and decks from 2018, newest first.
Correvio to Present at the 30th Annual Piper Jaffray Healthcare Conference
November 20, 2018
Correvio Reports Third Quarter 2018 Financial Results
November 6, 2018
Correvio to Report Third Quarter 2018 Financial Results on November 6, 2018
October 30, 2018
Correvio Announces Brinavess Eligibility for Patent Extension
October 29, 2018
Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019
October 23, 2018
Correvio to Participate In Upcoming Investor Conferences
September 20, 2018
Correvio Reports Preliminary Data Collected from >2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study
September 5, 2018
Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics
September 4, 2018
Correvio to Participate in Upcoming Investor Conferences
August 28, 2018
Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients
August 16, 2018
Correvio Reports Second Quarter 2018 Financial Results
August 14, 2018
Correvio Announces Brinavess® Selected as Potentially Eligible for Priority Review in China
August 14, 2018
Correvio To Report Second Quarter 2018 Financial Results On August 14, 2018
August 7, 2018
Correvio to present at the Canaccord Genuity 38th Annual Growth Conference
August 1, 2018
Correvio Announces At The Market Offering
July 10, 2018
Correvio Provides U.S. Regulatory Update for BRINAVESS
June 11, 2018
Brinavess Data Receives Top Award For Best Article Published In The Spanish Medical Journal EMERGENCIAS
June 6, 2018
Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV
May 17, 2018
Correvio Reports First Quarter 2018 Financial Results
May 15, 2018
Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals
May 15, 2018
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call
May 10, 2018
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 26, 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®
April 17, 2018
Cardiome Announces Fifteen Xydalba(TM) and Zevtera® Abstracts at ECCMID 2018
April 12, 2018
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds
April 6, 2018
Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission
April 2, 2018
Cardiome Announces Recent Insider Purchases
March 28, 2018
Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review
March 22, 2018
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
March 20, 2018
Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results
March 13, 2018
Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13
March 6, 2018
Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference
February 8, 2018
Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen
January 23, 2018
Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit
January 10, 2018